



Index

Note: Page numbers of article titles are in **boldface** type.

A

AAD. See *Acute aortic dissection (AAD)*.

ACC/AHA. See *American Heart Association/American College of Cardiology (ACC/AHA)*.

ACE inhibitors. See *Angiotensin-converting enzyme (ACE) inhibitors*.

ACLS. See *Acute Cardiac Life Support (ACLS)*.

Acute aortic dissection (AAD). **779–800**

aortography in, 787
biomarkers in, 785–786
classification of, 780–781
clinical manifestations of, 782–786
CT in, 788–789
differential diagnosis of, 785
echocardiography in, 787–788
imaging of, 786–790
incidence of, 780
intradural hematomas, 782
MRI in, 789–790
pathophysiology of, 779
physical findings in, 784–785
predisposing factors for, 780
symptoms of, 782–784
TEE in, 788
treatment of
 long-term, 796
 medical, 790–794
 surgical, 794–796

Acute Cardiac Life Support (ACLS), review of updated guidelines for. **873–880**
bradycardia, 878
medication administration, 876–877
rescue breaths, 877

Acute decompensated heart failure (ADHF). **737–758**
ancillary evaluation of, 742–746
clinical evaluation of, 740–742
clinical presentation of, 740
defined, 737–739
hemodynamic monitoring in, 746
hospitalizations due to, 737

precipitating factors in, 738

treatment of, 746–753

ACE inhibitors in, 752

Bi PAP in, 747

β -blockers in, 752

CPAP in, 747

device therapy in, 751

digoxin in, 753

diuretics in, 747–748

dobutamine in, 750

in-hospital, 746–748

inotropes in, 749–751

long-term, 752–753

milrinone in, 750–751

morphine sulfate in, 747

nesiritide in, 749

nitroglycerin in, 748–749

nitroprusside in, 749

oxygen in, 747

postdischarge management

 in, 753

spironolactone in, 753

ultrafiltration in, 751

vasodilators in, 748–749

Acute pulmonary embolism. **836–841**

described, 836

diagnosis of, CTPA in, 837–841

in critical care setting, diagnosis of,

 836–841

treatment of, 817–818

Acute thoracic cardiovascular emergencies.
CT and MRI of, **835–853**

ADHERE study. 748

ADHF. See *Acute decompensated heart failure (ADHF)*.

Alcohol withdrawal, sedative-hypnotics for. 888–889

American College of Cardiology/American Heart Association, ST elevation myocardial infarction guidelines. 767

American Heart Association/American College of Cardiology (ACC/AHA). 873–874

- Amiodarone
for atrial fibrillation, 860–864, 866
for cardiac arrest, 877
for cardiogenic shock, 765
- Aneurysm(s), left ventricular, STEMI and, 701
- Angiography
coronary, in UA/NSTEMI evaluation, 715–716
pulmonary, in pulmonary thromboembolic disease evaluation, 814
- Angiotensin-converting enzyme (ACE) inhibitors
for acute STEMI, 698–699
for ADHF, 752
- Antiarrhythmic agents, for cardiac arrest, 876–877
- Anticoagulant(s), for UA/NSTEMI, 724–727
- Anti-ischemic agents, for UA/NSTEMI, 718–727
- Antiplatelet agents, for UA/NSTEMI, 720–724
- Antiplatelet therapy, for acute STEMI, 696–697
- Antithrombin agents, for UA/NSTEMI, 724–727
- Antithrombotic agents, for acute STEMI, 697–698
- Aortic dissection, 841–845
clinical presentation of, 841–842
described, 841
diagnosis of, 842–845
- Aortography, in AAD, 787
- Aripiprazole, in delirium management, 888
- Arrhythmia(s)
cardiac, atrial fibrillation, in critically ill patients, 855–872. See also *Atrial fibrillation, in critically ill patients.*
STEMI and, 702
treatment of, 823
- Aspirin, for UA/NSTEMI, 720–721
- Atrial fibrillation
causes of, 855–857
clinical presentation of, 859
conditions associated with, 855–857
defined, 855, 856
- hemodynamic consequences of, 858–859
in critically ill patients, 855–872
management of
acute rate control
in, 860–861
anticoagulation in ICU, 867–868
biphasic waveform defibrillators in, 865
β-blockers in, 860
calcium channel blockers in, 860
digoxin in, 860–861
electrical cardioversion in, 865–866
pharmacologic cardioversion in, 861–865
in ICU, long-term outcome of, 868–869
management of, 859–868
pathophysiology of, 856, 858
prevalence of, 855
prevention of, 868
STEMI and, 702
- Atrial flutter, STEMI and, 702
-
- B**
- Benzodiazepine(s), in alcohol withdrawal, 888–889
- Bi PAP. See *Biphasic positive airway pressure (Bi PAP).*
- Biochemical markers, in UA/NSTEMI evaluation, 713–714
- Biomarker(s)
cardiac, in acute STEMI evaluation, 688
in AAD, 785–786
- Biphasic positive airway pressure (Bi PAP), for ADHF, 747
- Biphasic waveform defibrillators, for atrial fibrillation, 865
- β-blockers
for acute STEMI, 698
for ADHF, 752
for atrial fibrillation, 860
for UA/NSTEMI, 720
- Bradycardia
defined, 878
treatment of, 878
- Bumetanide, for cardiogenic shock, 765

C

- Calcium channel blockers
for atrial fibrillation, 860
for UA/NSTEMI, 720
- Cardiac arrest
medications for, administration of, 876–877
rhythms encountered during, 876
- Cardiac arrhythmias, atrial fibrillation, in critically ill patients, 855–872.
See also *Atrial fibrillation, in critically ill patients.*
- Cardiac biomarkers, in acute STEMI evaluation, 688
- Cardiac catheterization, in UA/NSTEMI evaluation, 715–716
- Cardiogenic shock
criteria for, 759–760
defined, 759
management of
conventional, 764
mechanical support devices in, 771–772
new approaches in, 772–773
pharmacologic, 765–766
myocardial infarction complications of, 759–777
clinical presentation of, 761–763
incidence of, 760
initial stabilization of, 763–766
management of
IABP in, 766–767
reperfusion strategies in, 767–771
pathogenesis of, 760–761
STEMI and, 701–702
- Cardiopulmonary resuscitation (CPR)
review of updated guidelines for, 873–880
amount of shocks, 874–875
interruption of chest compressions, 875–876
number of compressions, 874
paramedics' response to cardiac arrest in field, 876
- Cardiovascular disease
abnormal physiologic mechanisms in, 893
drugs for, depression resulting from, 890–893
- Cardiovascular system, stress effects on, 894–895
- Cardioversion
electrical, for atrial fibrillation, 865–866
pharmacologic, for atrial fibrillation, 861–865
- Catheterization, cardiac, in UA/NSTEMI evaluation, 715–716
- Chest radiography, in AAD, 786–787
- Chronic thromboembolic pulmonary hypertension (CTEPH), treatment of, 818–819
- Clopidogrel, for acute STEMI, 697
- Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial, 721
- Clozapine, in delirium management, 888
- Computed tomography (CT)
in AAD, 788–789
of acute thoracic cardiovascular emergencies, 835–853
pulmonary embolism protocol, in pulmonary thromboembolic disease evaluation, 813–814
- Computed tomography pulmonary angiography (CTPA), in acute pulmonary embolism diagnosis, 837–841
- Continuous positive airway pressure (CPAP), for ADHF, 747
- Coronary angiography, in UA/NSTEMI evaluation, 715–716
- Coronary artery bypass, for acute STEMI, 696
- Coronary artery disease, prevalence of, 709
- Coronary disease, in critical care setting, advanced imaging for, 845–849
- Coronary revascularization, for UA/NSTEMI, 727–729
- CPAP. See *Continuous positive airway pressure (CPAP).*
- CPR. See *Cardiopulmonary resuscitation (CPR).*
- CT. See *Computed tomography (CT).*
- CTEPH. See *Chronic thromboembolic pulmonary hypertension (CTEPH).*
- CTPA. See *Computed tomography pulmonary angiography (CTPA).*
- CURE trial. See *Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial.*

D

- Defibrillator(s), biphasic waveform, for atrial fibrillation, 865
- Delirium, **881–889**
causes of, 884–885
changes associated with, 882–883
defined, 882
described, 881–882
management of, 883–885
haloperidol in, 886–888
nonpharmacologic, 885–886
pharmacologic, 886–889
side effects of, 886–889
vs. treatment, 884–885
risk factors for, 883
- Delirium tremens, sedative-hypnotics for, 888–889
- Depression, **889–894**
abnormal physiologic mechanisms in, 893
cardiovascular disease and, 890–894
described, 889–890
drugs causing, 890
mood disorders associated with, 890
myocardial infarction and, 890–894

Device therapy, for ADHF, 751

Digoxin, 860–861
for ADHF, 753
for atrial fibrillation, 862, 863

Diltiazem, for atrial fibrillation, 862

Diuretic(s), for ADHF, 747–748

Dobutamine
for ADHF, 750
for cardiogenic shock, 765–766

Dofetilide, for atrial fibrillation, 864–866

Dopamine
for bradycardia, 878
for cardiogenic shock, 765, 766

Drug(s)
for cardiogenic shock, 765–766
in delirium management, 886–889

E

ECC. See *Emergency Cardiovascular Care (ECC)*.

ECG. See *Electrocardiogram (ECG)*.

Echocardiography
in AAD, 787–788
in pulmonary hypertension diagnosis, 812–813

ECLS. See *Extracorporeal life support (ECLS)*.

Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events (ESSENCE) trial, 725

Electrical cardioversion, for atrial fibrillation, 865–866

Electrocardiography (ECG)
in acute STEMI evaluation, 687
in pulmonary hypertension diagnosis, 809–811
in UA/NSTEMI evaluation, 713

Embolism(i), pulmonary, acute, 836–841.
See also *Acute pulmonary embolism*.

Emergency Cardiovascular Care (ECC), 873

Endothelin antagonists, for pulmonary hypertension, 826

ENhanced Recovery In Coronary Heart Disease (ENRICHD), 891–892

ENRICHD. See *ENhanced Recovery In Coronary Heart Disease (ENRICHD)*.

Epinephrine
for bradycardia, 878
for cardiogenic shock, 766

Esmolol, for atrial fibrillation, 862

ESSENCE trial. See *Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events (ESSENCE) trial*.

European Society of Cardiology, 856

Extracorporeal life support (ECLS), in cardiogenic shock management, 772

F

Factor X inhibitors, for UA/NSTEMI, 726–727

Fast Revascularization During Instability in Coronary Artery Disease (FRISC) trial, 726

Fibrillation(s), ventricular, STEMI and, 702–703

Fibrinolysis, for acute STEMI, contraindications to, 695

Fibrinolytic therapy
for acute STEMI, 691–694
in cardiogenic shock management, 767–768

Flecainide, for atrial fibrillation, 866

Fondaparinux, for UA/NSTEMI, 726–727

Food and Drug Administration, 725

Free wall rupture, left ventricular, STEMI and, 700–701

FRISC trial. See *Fast Revascularization During Instability in Coronary Artery Disease (FRISC) trial*.

Furosemide, for cardiogenic shock, 765

G

Gas exchange, in pulmonary hypertension diagnosis, 811–812

Glycoprotein IIb/IIIa inhibitors for acute STEMI, 698 for UA/NSTEMI, 721–724

H

Haloperidol, in delirium management, 886–888

Hematoma(s), intradural, 782

Hemodynamic parameters, normal, 809

Heparin

low-molecular-weight,
for UA/NSTEMI, 725–726
unfractionated, for UA/NSTEMI, 724–725

Hirudin, for UA/NSTEMI, 726

Hypertension

pulmonary, in critical care setting, 801–834. See also *Pulmonary hypertension, in critical care setting*.
pulmonary arterial, treatment of, 820–823

Hypotension, treatment of, 820–823

Hypoxemia, treatment of, 823

Hypertension, pulmonary arterial, adjunctive therapy for, 823–825

I

IABP. See *Intra-aortic balloon pump (IABP)*.

Ibutilide, for atrial fibrillation, 864, 866

ICTUS study. See *Invasive versus Conservative Treatment in Unstable Coronary Syndrome (ICTUS) study*.

Inotrope(s), for ADHF, 749–751

Intra-aortic balloon pump (IABP)

for acute STEMI, 699
in cardiogenic shock management, 766–767

Intradural hematomas, 782

Invasive versus Conservative Treatment in Unstable Coronary Syndrome (ICTUS) study, 728

K

Kussmaul's sign, 763

L

Left ventricular aneurysm, STEMI and, 701

Left ventricular failure, STEMI and, 701–702

Left ventricular free wall rupture, STEMI and, 700–701

Low-molecular-weight heparin, for UA/NSTEMI, 725–726

M

Magnetic resonance imaging (MRI)

in AAD, 789–790
of acute thoracic cardiovascular emergencies, 835–853

Metoprolol, for atrial fibrillation, 862

Milrinone

for ADHF, 750–751
for cardiogenic shock, 765, 766

Mitral regurgitation, STEMI and, 699–700

Mood disorders, depression and, 890

Morphine sulfate, for ADHF, 747

MRI. See *Magnetic resonance imaging (MRI)*.

Myocardial infarction

acute, causes of, nonatherosclerotic, 686
cardiogenic shock complicating, 759–777. See also *Cardiogenic shock, myocardial infarction complications of*.
drugs for, depression resulting from, 893

N

National Heart Attack Alert Program, 689–690

- Nesiritide, for ADHF, 749
- Nitrate(s), for UA/NSTEMI, 718–720
- Nitroglycerin
for ADHF, 748–749
for cardiogenic shock, 765
- Nitroprusside
for ADHF, 749
for cardiogenic shock, 765
- Nitrous oxide (NO), inhaled, for pulmonary hypertension, 831
- NO. See *Nitrous oxide (NO)*.
- Norepinephrine, for cardiogenic shock, 765, 766
- North American Society of Pacing and Electrophysiology, 856
- O**
- OASIS-5 trial. See *Organization to Assess Strategies for Ischemic Syndromes (OASIS)-5 trial*.
- Olanzapine, in delirium management, 888
- Organization to Assess Strategies for Ischemic Syndromes (OASIS)-5 trial, 727
- Oxygen, for ADHF, 747
- P**
- Percutaneous cardiopulmonary bypass, in cardiogenic shock management, 772
- Percutaneous coronary intervention, in cardiogenic shock management, 768–771
- Pericarditis, STEMI and, 703–704
- Pharmacologic cardioversion, for atrial fibrillation, 861–865
- Phenylephrine, for cardiogenic shock, 765
- Phosphodiesterase-5 inhibitor, for pulmonary hypertension, 826–827
- Physical restraint, in delirium management, 885–886
- Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)–TIMI 22 study, 728
- Primary PCI, for acute STEMI, 694–696
- Procainamide
for atrial fibrillation, 864
for cardiac arrest, 878
- Propafenone, for atrial fibrillation, 866
- Propranolol, for atrial fibrillation, 862
- Prostacyclin analogues, for pulmonary hypertension, 827–831
- PROVE IT–TIMI 22 study, 728
- Psychotropic drugs, torsades de Pointes due to, 886–887
- Pulmonary angiography, in pulmonary thromboembolic disease evaluation, 814
- Pulmonary arterial hypertension
adjunctive therapy for, 823–825
treatment of, 820–823
- Pulmonary embolism, acute, 836–841. See also *Acute pulmonary embolism*.
- Pulmonary embolism protocol CT, in pulmonary thromboembolic disease evaluation, 813–814
- Pulmonary function testing, in pulmonary hypertension diagnosis, 811–812
- Pulmonary hypertension
chronic thromboembolic, treatment of, 818–819
in critical care setting, 801–834
biomarkers in, 815
classification of, 801–804
clinical assessment of, 805–813
clinical characteristics of, 805–813
defined, 801–804
diagnosis of, 805–813
ECG in, 809–811
echocardiography in, 812–813
gas exchange in, 811–812
pulmonary function testing in, 811–812
hemodynamics in, 816–817
hypoxemia in, acute worsening of, causes of, 810
pathogenesis of, 804–805
physiology of, 801–804
pulmonary arterial hypertension
adjunctive therapy for, 823–825
treatment of, 820–823
pulmonary thromboembolic disease, evaluation for, 813–815
rapid deterioration in, causes of, 810
thromboembolic disease, treatment of, 817–819

- treatment of
endothelin antagonists
in, 826
inhaled NO in, 831
phosphodiesterase-5
inhibitor in, 826–827
prostacyclin analogues in,
827–831
surgical, 831–832
- WHO classification of, 803–804, 808
- Pulmonary thromboembolic disease,
evaluation for, 813–815
- Q**
- Quetiapine, in delirium management, 888
- Quinidine, for atrial fibrillation, 866
- R**
- Radiography, chest, in AAD, 786–787
- Regurgitation, mitral STEMI and, 699–700
- Reperfusion strategies
for acute STEMI, 691
in cardiogenic shock management,
767–771
fibrinolytic therapy, 767–768
percutaneous coronary
intervention, 768–771
surgical revascularization, 771
- Restraint(s), physical, in delirium
management, 885–886
- Revascularization
coronary, for UA/NSTEMI, 727–729
surgical, in cardiogenic shock
management, 771
- Right ventricular infarction, STEMI
and, 701
- Risperidone, in delirium management, 888
- Rupture, ventricular septal, STEMI
and, 700
- S**
- SADHAT. See *Sertraline Anti-Depressant Heart Attack Trial (SADHAT)*.
- SADHEART. See *Sertraline Anti-Depressant Heart Attack Trial (SADHAT)*.
- Sedative-hypnotics, in alcohol withdrawal,
888–889
- Sertraline Anti-Depressant Heart Attack
Trial (SADHAT), 891–892
- Shock, cardiogenic. See *Cardiogenic shock*.
- SHOCK trial, 768, 769, 772–773
- SMASH trial. See *Swiss Multicenter of Angioplasty Shock (SMASH) trial*.
- Spironolactone, for ADHF, 753
- Statins, for UA/NSTEMI, 728–729
- STEMI. See *ST-segment myocardial infarction (STEMI)*.
- Stress, cardiovascular system effects of,
894–895
- ST-segment myocardial infarction (STEMI)
acute
arrhythmias in patients with, 702
atrial fibrillation/flutter due to,
702
cardiac biomarkers in, 688
cardiogenic shock due to,
701–702
clinical presentation of,
686–687
complications of, 699–704
critical care perspective on,
685–707
differential diagnosis of, 688, 689
ECG in, 687
evaluation of, 686–687
imaging in, 688
left ventricular aneurysm due to,
701
left ventricular failure due to,
701–702
left ventricular free wall rupture
due to, 700–701
mitral regurgitation due to,
699–700
pericarditis due to, 703–704
physical examination in, 687
prognosis of, 704
recurrent ischemic events due to,
703
right ventricular infarction due
to, 701
symptoms of, 686–687
tachycardia due to, 702–703
treatment of, 688–699
ACE inhibitors in, 698–699
adjunctive therapy in, 696
antiplatelet therapy in,
696–697
antithrombotic agents in,
697–698
β-blockers in, 698
coronary artery bypass in,
696
discharge care in, 704–705

- ST-segment myocardial (*continued*)
 fibrinolysis in,
 contraindications to, 695
 fibrinolytic therapy in, 691–694
 glycoprotein IIb/IIIa inhibitors in, 698
 IABP in, 699
 in-hospital, 704–705
 primary PCI in, 694–696
 reperfusion strategy in, 691
 ventricular fibrillation due to, 702–703
 ventricular septal rupture due to, 700
 causes of, 685–686
 prevalence of, 685
 prognosis of, 685
- Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial, 725
- Swiss Multicenter of Angioplasty Shock (SMASH) trial, 768
- SYNERGY trial. See *Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial*.
-
- T**
- Tachycardia, STEMI and, 702–703
- TACTICS trial. See *Thrombolysis and Counterpulsation to Improve Cardiogenic Shock Survival (TACTICS) trial*.
- TEE. See *Transesophageal echocardiography (TEE)*.
- Thienopyridine(s), for UA/NSTEMI, 721
- Third World Symposium of Pulmonary Hypertension, 803–804
- Thrombin inhibitors, for UA/NSTEMI, 726–727
- Thromboembolic disease, treatment of, 817–819
- Thrombolysis and Counterpulsation to Improve Cardiogenic Shock Survival (TACTICS) trial, 766
- Tilarginine Acetate Injection in a Randomized International Study in Unstable MI Patients with
- Cardiogenic Shock (TRIUMPH) trial, 773
- Torsades de Pointes, psychotropic drugs and, 886–887
- Transesophageal echocardiography (TEE), in AAD, 788
- Transthoracic echocardiography (TTE), in AAD, 787
- TRIUMPH trial. See *Tilarginine Acetate Injection in a Randomized International Study in Unstable MI Patients with Cardiogenic Shock (TRIUMPH) trial*.
- TTE. See *Transthoracic echocardiography (TTE)*.
-
- U**
- UA/NSTEMI. See *Unstable angina/non-ST elevation myocardial infarction*.
- Ultrafiltration, for ADHF, 751
- Unfractionated heparin, for UA/NSTEMI, 724–725
- Unstable angina/non-ST elevation myocardial infarction (UA/NSTEMI), 709–735
 complications of, 716
 described, 709
 diagnostic evaluation of, 713–716
 cardiac catheterization in, 715–716
 coronary angiography in, 715–716
 ECG in, 713
 noninvasive testing in, 714–715
 pathogenesis of, 710–711
 signs and symptoms of, 711–713
 treatment of, 716–730
 anticoagulants in, 724–727
 anti-ischemic agents in, 718–727
 antiplatelet agents in, 720–724
 antithrombin agents in, 724–727
 aspirin in, 720–721
 β-blockers in, 720
 calcium channel blockers in, 720
 coronary revascularization in, 727–729
 factor X inhibitors in, 726–727
 follow-up care, 729–730
 fondaparinux in, 726–727
 general measures in, 717–718
 glycoprotein IIb/IIIa inhibitors in, 721–724
 hirudin in, 726
 long-term, 729–730
 low-molecular-weight heparin in, 725–726

nitrates in, 718–720
statins in, 728–729
thienopyridines in, 721
thrombin inhibitors in, 726–727
unfractionated heparin in,
724–725

V

VADs. See *Ventricular assist devices (VADs)*.

Value of First Day Angiography/
Angioplasty in Evolving Non-ST
Segment Elevation Myocardial
Infarction: An Open Multicenter
Randomized Trial (VINO), 728

Vasodilator(s), for ADHF, 748–749

Ventilation/perfusion scanning, in
pulmonary thromboembolic disease
evaluation, 814

Ventricular assist devices (VADs), in
cardiogenic shock management, 772

Ventricular fibrillation, STEMI and,
702–703

Ventricular septal rupture, STEMI and, 700

Verapamil, for atrial fibrillation, 862, 863

VINO. See *Value of First Day Angiography/
Angioplasty in Evolving Non-ST
Segment Elevation Myocardial
Infarction: An Open Multicenter
Randomized Trial (VINO)*.

W

WHO. See *World Health Organization (WHO)*.

World Health Organization (WHO),
classification of pulmonary
hypertension, 803–804, 808

Z

Ziprasidone, in delirium management, 888



